Molecules [e.g., plasma derived C1-INH (59)] and antibodies [e.g., sutimlimab (60) and ANX005 (61)] targeting at the CP offers selective modulation of complement activation in GBS and NMOSD (62–64). The gene discussed is CP; the disease is Guillain-Barre syndrome.